121 related articles for article (PubMed ID: 38479337)
1. Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines.
Zeissig MN; Hewett DR; Mrozik KM; Panagopoulos V; Wallington-Gates CT; Spencer A; Dold SM; Engelhardt M; Vandyke K; Zannettino ACW
Leuk Res; 2024 Apr; 139():107469. PubMed ID: 38479337
[TBL] [Abstract][Full Text] [Related]
2. Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells
Zeissig MN; Hewett DR; Panagopoulos V; Mrozik KM; To LB; Croucher PI; Zannettino ACW; Vandyke K
Haematologica; 2021 Dec; 106(12):3176-3187. PubMed ID: 33147936
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism and Clinical Significance of
Wang YR; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):138-145. PubMed ID: 38387912
[TBL] [Abstract][Full Text] [Related]
4. Reduced response of IRE1α/Xbp-1 signaling pathway to bortezomib contributes to drug resistance in multiple myeloma cells.
Xu X; Liu J; Huang B; Chen M; Yuan S; Li X; Li J
Tumori; 2017 May; 103(3):261-267. PubMed ID: 27647225
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
6. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1.
Vandyke K; Zeissig MN; Hewett DR; Martin SK; Mrozik KM; Cheong CM; Diamond P; To LB; Gronthos S; Peet DJ; Croucher PI; Zannettino ACW
Cancer Res; 2017 Oct; 77(20):5452-5463. PubMed ID: 28855206
[TBL] [Abstract][Full Text] [Related]
7. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma.
Mimura N; Fulciniti M; Gorgun G; Tai YT; Cirstea D; Santo L; Hu Y; Fabre C; Minami J; Ohguchi H; Kiziltepe T; Ikeda H; Kawano Y; French M; Blumenthal M; Tam V; Kertesz NL; Malyankar UM; Hokenson M; Pham T; Zeng Q; Patterson JB; Richardson PG; Munshi NC; Anderson KC
Blood; 2012 Jun; 119(24):5772-81. PubMed ID: 22538852
[TBL] [Abstract][Full Text] [Related]
8. Protein Kinase D 1 Predicts Poor Treatment Response and Unfavorable Survival of Bortezomib-Based Treatment, and Its Knockdown Enhances Drug Sensitivity to Bortezomib in Multiple Myeloma.
Li X; Yang Y; Yi X
Technol Cancer Res Treat; 2020; 19():1533033820936770. PubMed ID: 32799769
[TBL] [Abstract][Full Text] [Related]
9. Identifying bias in CCR1 antagonists using radiolabelled binding, receptor internalization, β-arrestin translocation and chemotaxis assays.
Gilchrist A; Gauntner TD; Fazzini A; Alley KM; Pyen DS; Ahn J; Ha SJ; Willett A; Sansom SE; Yarfi JL; Bachovchin KA; Mazzoni MR; Merritt JR
Br J Pharmacol; 2014 Nov; 171(22):5127-38. PubMed ID: 24990525
[TBL] [Abstract][Full Text] [Related]
10. SGK Kinase Activity in Multiple Myeloma Cells Protects against ER Stress Apoptosis via a SEK-Dependent Mechanism.
Hoang B; Shi Y; Frost PJ; Mysore V; Bardeleben C; Lichtenstein A
Mol Cancer Res; 2016 Apr; 14(4):397-407. PubMed ID: 26869290
[TBL] [Abstract][Full Text] [Related]
11. Intratibial injection of human multiple myeloma cells in NOD/SCID IL-2Rγ(null) mice mimics human myeloma and serves as a valuable tool for the development of anticancer strategies.
Schueler J; Wider D; Klingner K; Siegers GM; May AM; Wäsch R; Fiebig HH; Engelhardt M
PLoS One; 2013; 8(11):e79939. PubMed ID: 24223204
[TBL] [Abstract][Full Text] [Related]
12. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
13. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells.
Oba Y; Lee JW; Ehrlich LA; Chung HY; Jelinek DF; Callander NS; Horuk R; Choi SJ; Roodman GD
Exp Hematol; 2005 Mar; 33(3):272-8. PubMed ID: 15730850
[TBL] [Abstract][Full Text] [Related]
14. The Mucolipin TRPML2 Channel Enhances the Sensitivity of Multiple Myeloma Cell Lines to Ibrutinib and/or Bortezomib Treatment.
Santoni G; Amantini C; Maggi F; Marinelli O; Santoni M; Morelli MB
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053255
[TBL] [Abstract][Full Text] [Related]
15. Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.
Ling SC; Lau EK; Al-Shabeeb A; Nikolic A; Catalano A; Iland H; Horvath N; Ho PJ; Harrison S; Fleming S; Joshua DE; Allen JD
Haematologica; 2012 Jan; 97(1):64-72. PubMed ID: 21993678
[TBL] [Abstract][Full Text] [Related]
16. CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease.
Dairaghi DJ; Oyajobi BO; Gupta A; McCluskey B; Miao S; Powers JP; Seitz LC; Wang Y; Zeng Y; Zhang P; Schall TJ; Jaen JC
Blood; 2012 Aug; 120(7):1449-57. PubMed ID: 22618707
[TBL] [Abstract][Full Text] [Related]
17. The chemokine CCL5 induces CCR1-mediated hyperalgesia in mice inoculated with NCTC 2472 tumoral cells.
Pevida M; Lastra A; Meana Á; Hidalgo A; Baamonde A; Menéndez L
Neuroscience; 2014 Feb; 259():113-25. PubMed ID: 24316469
[TBL] [Abstract][Full Text] [Related]
18. CCR1 as a target for multiple myeloma.
Vallet S; Anderson KC
Expert Opin Ther Targets; 2011 Sep; 15(9):1037-47. PubMed ID: 21609295
[TBL] [Abstract][Full Text] [Related]
19. Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model.
Menu E; De Leenheer E; De Raeve H; Coulton L; Imanishi T; Miyashita K; Van Valckenborgh E; Van Riet I; Van Camp B; Horuk R; Croucher P; Vanderkerken K
Clin Exp Metastasis; 2006; 23(5-6):291-300. PubMed ID: 17086356
[TBL] [Abstract][Full Text] [Related]
20. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
